CP2c-Targeting Peptide Anticancer Agent Patent Grant
Summary
USPTO granted patent US12605453B2 to Industry-University Cooperation Foundation Hanyang University on April 21, 2026, covering a CP2c-targeting peptide-based anticancer agent. The peptide binds to transcription factor CP2c to inhibit the formation of CP2c homotetramers and CP2c/CP2b/PIAS1 heterohexamers, inducing cancer cell-specific cell death. A fatty acid is bound to the peptide for in vivo stability. The patent contains 5 claims.
What changed
USPTO issued patent US12605453B2 to Industry-University Cooperation Foundation Hanyang University on April 21, 2026, granting exclusive rights to a CP2c-targeting peptide anticancer agent. The granted claims cover the peptide composition and its mechanism of binding to transcription factor CP2c to inhibit transcription factor complex formation, combined with a fatty acid moiety for in vivo stability. Five claims were allowed.
Pharmaceutical and biotechnology companies developing transcription factor-targeting cancer therapeutics should review the patent scope to assess freedom-to-operate implications. The assigned CPC classifications (A61K 47/64, C07K 14/00) indicate peptide chemistry and pharmaceutical composition claims, which may affect related product development programs.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CP2C-targeting peptide-based anticancer agent
Grant US12605453B2 Kind: B2 Apr 21, 2026
Assignee
Industry-University Cooperation Foundation Hanyang University
Inventors
Chul Geun Kim, Min Young Kim, Chan Gil Kim, Seung Han Son, Ji Sook Kim, Sung Woo Choi, Seol Eui Lee, Min Sung Chung, Dong Sun Park, Sang Won Lee, Jae Min Jeong, Dong Ho Choi, Ki Seok Jang
Abstract
The presented invention relates to a CP2c-targeting peptide-based anticancer agent. A CP2c-targeting peptide according to the presented invention binds to transcription factor CP2c to inhibit the formation of transcription factor CP2c complexes (CP2c homotetramer and CP2c/CP2b/PIAS1 heterohexamer), thereby inducing cancer cell-specific cell death. A fatty acid is bound to the peptide to ensure stability enabling long-term sustenance in vivo.
CPC Classifications
A61K 47/64 C07K 14/00
Filing Date
2020-04-01
Application No.
17600760
Claims
5
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.